The Manufacture And Clinical Study Of Pinellia Tuber Oral Solution

Pinellia tuber is the dry tuber of Pinellia ternate (Thnub. )Breit.It has many clinical applications .It has alkaloid, polysaccharide, organic acid and guanosine etc. This topic established the manufacture tcchnology and quality standard of pinellia tuber liquor, and study the anti-emesis action of pinellia tuber liquor. At the same time, we use efedrina and guanosine as contrast study the fingerprint of pinellia tuber . The follows are the results:1 To establish the manufacture technology of pinellia tuber oral solution. Its propities was stable.2 To establish the identification method of pinellia tuber oral solution , identificated 5 sample,It has the same color smudge at the same position3 To establish the determination method of pinellia tuber oral solution determinated 5 samples, Its average content of alkaloid in pinellia tuber oral solution is 0.193mg·10ml-14 In the clinical experiment of radiotherapy of tumor, The total effective rate was 91.51% in the pinellia tuber group and was 87.00% in mono-radiotherapy group(P<0.05); The CR was 59.43% in the pinella tuber group and was 53.00% in the mono-radiotherapy group(P<0.05)5 In the clinical experiment of Chemotherapy of tumor, The total effective rate was 90.24% in the pinellia tuber combination with ondansetron group and was 75.49% in the match group(P <0.05); The CR was 24.07% in the pinellia tuber combination with ondansetron group and was 15.69% in the match group(P <0.01).6 To establish fingerprint chromatogramap of Pinellia tuber, three peaks were shown in the chromatogramap of Ethanol extraction of pinellia tuber, The Rt were11.51, 12.54, 15.97min, respectively.and three peaks were shown in the chromatogramap of water extraction of pinellia tuber, The Rt were 10.72, 11.95, 12.09min, respectively.The results suggested that pinellia tuber have many actions such as antiemetic and anti-neoplasia, studying the active chemical constituents and its mechanisms in pinelliatuber may be great value in screening new antiemetic and anti-neoplasia drugs.